Holen Sie sich die Stockscreener-App
9.02
3.09%
0.27
Vorhandelsmarkt:
9.48
0.46
+5.10%
Schlusskurs vom Vortag:
$8.75
Offen:
$8.66
24-Stunden-Volumen:
836.02K
Relative Volume:
1.55
Marktkapitalisierung:
$487.91M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-5.7089
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-6.53%
1M Leistung:
-2.17%
6M Leistung:
+60.50%
1J Leistung:
+181.00%
1-Tages-Spanne:
$8.48
$9.47
1-Wochen-Bereich:
$8.29
$10.11
52-Wochen-Spanne:
$2.315
$10.11
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
9.02 | 473.30M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
How Fulcrum Therapeutics Inc. stock responds to policy changesTrade Exit Summary & Expert Curated Trade Ideas - newser.com
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - The Manila Times
Fulcrum Therapeutics to Present Phase 1b PIONEER Trial Data on Pociredir for Sickle Cell Disease at ASH 2025 - Quiver Quantitative
Will Fulcrum Therapeutics Inc. stock gain from strong economyJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesTrade Risk Summary & Safe Entry Momentum Tips - newser.com
Can Fulcrum Therapeutics Inc. stock resist sector downturns2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.July 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
How sustainable is Fulcrum Therapeutics Inc. stock dividend payoutMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chartQuarterly Investment Review & Reliable Volume Spike Alerts - newser.com
Statistical indicators supporting Fulcrum Therapeutics Inc.’s strengthMarket Growth Review & Pattern Based Trade Signal System - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.Watch List & Free Risk Controlled Daily Trade Plans - newser.com
What is Leerink Partnrs' Estimate for FULC FY2025 Earnings? - MarketBeat
FY2025 EPS Forecast for Fulcrum Therapeutics Cut by Analyst - MarketBeat
FY2025 EPS Estimate for Fulcrum Therapeutics Cut by Analyst - MarketBeat
How to build a dashboard for Fulcrum Therapeutics Inc. stockBreakout Watch & Verified High Yield Trade Plans - newser.com
Why Fulcrum Therapeutics Inc. stock is in analyst buy zone2025 Short Interest & Fast Gaining Stock Reports - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Macro Impact & Short-Term High Return Strategies - newser.com
Will Fulcrum Therapeutics Inc. continue its uptrendPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-11-02 22:53:39 - newser.com
Why Fulcrum Therapeutics Inc. stock remains on buy listsWeekly Trade Recap & Fast Entry High Yield Tips - newser.com
Signal strength of Fulcrum Therapeutics Inc. stock in tech scannersJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
Fulcrum Therapeutics Inc. stock volume spike explainedMarket Risk Summary & Capital Protection Trade Alerts - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityMarket Movement Recap & Technical Entry and Exit Tips - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen - MarketBeat
What is HC Wainwright's Estimate for FULC Q1 Earnings? - MarketBeat
How institutional buying supports Fulcrum Therapeutics Inc. stockJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Price Target Raised to $7.00 - MarketBeat
Published on: 2025-10-31 05:47:11 - newser.com
Is Fulcrum Therapeutics Inc. trending in predictive chart modelsBreakout Watch & High Return Trade Guides - newser.com
How to forecast Fulcrum Therapeutics Inc. trends using time series - newser.com
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights: Promising Advances in Sickle ... By GuruFocus - Investing.com Canada
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights - GuruFocus
Fulcrum Therapeutics (FULC) Price Target Increased by 10.32% to 12.46 - MSN
RBC Capital Updates Fulcrum Therapeutics (FULC) Price Target Ami - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Piper Sandler Raises Price Target on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):